Alicia Broto, Carlos Piñero-Lambea, Carolina Segura-Morales, Anne P Tio-Gillen, Wendy W J Unger, Raul Burgos, Rocco Mazzolini, Samuel Miravet-Verde, Bart C Jacobs, Josefina Casas, Ruth Huizinga, Maria Lluch-Senar, Luis Serrano
A non-pathogenic Mycoplasma pneumoniae-based chassis is leading the development of live biotherapeutics (LBPs) for respiratory diseases. However, reports connecting Guillain-Barré syndrome (GBS) cases to prior M. pneumoniae infections represent a concern for exploiting such a chassis. Galactolipids, especially galactocerebroside (GalCer), are considered the most likely M. pneumoniae antigens triggering autoimmune responses associated with GBS development. In this work, we generated different strains lacking genes involved in galactolipids biosynthesis...
April 26, 2024: Microbes and Infection